Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines. WALTHAM, Mass. and HALLE (Saale),
Investors · These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome
Focused on cost and process efficiencies, we deliver innovative technologies and solutions that help set new standards in bioprocessing. 2020-07-30 · Global Head of Investor Relations (781) 419-1881 investors@repligen.com. REPLIGEN CORPORATION: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, amounts in thousands, 2020-02-06 · Global Head of Investor Relations (781) 419-1881 investors@repligen.com. Related Articles. More articles issued by Repligen Corporation More articles related to: Company Announcement Repligen Technical Support; XCell Lab System; About; Precision Engineering; Investor Contacts and Alerts; FAQ Login. Returning Customers Sign In. Sign in with a Get the latest price and volume on Repligen Corp in IBD stock charts.
Repligen Aktie . 0 Kommentare. Autor abonnieren . 0.
These forward looking statements reflect management’s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law. Repligen Contact: Sondra S. Newman Global Head of Investor Relations
Andrea Murphy, Hank Tucker Forbes: November 19, 2020: Repligen CEO Tony Hunt Knows Why Success Takes Time: Marilyn Munch Investor's Business Daily: October 28, 2020: Repligen strengthens downstream offering with $200m ARTeSYN acquisition: Dan Stanton BioProcess International: October 8, 2020: Navigo and Repligen Team on COVID-19 About Repligen. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide. Focused on cost and process efficiencies, we deliver innovative technologies and solutions that help set new standards in bioprocessing.
Repligen Investor Relations Contact Information Email: investors@repligen.com 781.419.1881. Stock Certificate Contact. For questions about your shares
Repligen introduces novel affinity resin for the purification of the SARS CoV-2 Spike Protein for vaccine development and manufacturing. NGL COVID-19 Spike Protein Affinity Resin binds the SARS-CoV-2 Spike Protein receptor binding domain (RBD) to yield exceptional purity in a single chromatography step. Repligen Investor Relations Contact Information Email: investors@repligen.com 781.419.1881. Stock Certificate Contact. For questions about your shares, replacement of Repligen: #15.
The conference call will be accessible by dialing
2020-10-22
Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held C
Global Head of Investor Relations (781) 419-1881 investors@repligen.com
Investor Relations Global Contacts Repligen Corp RGEN Morningstar Rating Rating as of Apr 6, 2021. Quote Stock
2019-10-23
2021-03-17
Repligen Contact: Sondra S. Newman Global Head of Investor Relations (781) 419-1881 investors@repligen.com
Global Head of Investor Relations (781) 419-1881 investors@repligen.com REPLIGEN CORPORATION: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, amounts in thousands,
Global Head of Investor Relations (781) 419-1881 investors@repligen.com . REPLIGEN CORPORATION: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, amounts in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2020 : 2019 : 2020 : 2019 : Revenue: Product revenue $ 87,432 $ 70,670 $
2019-02-21
2020-02-06
2019-07-24
2019-11-01
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. 2020-05-06
2021-04-09
Repligen General Information Description.
Medborgarkontoret rågsved
Tony Hunt - President and These forward-looking statements reflect management’s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law. Repligen Contact: Sondra S. Newman Global Head of Investor Relations (781 Repligen Contact: Sondra S. Newman Global Head of Investor Relations(781) 419-1881investors@repligen.com. Repligen Corporation.
View Comments and Join the Discussion! Need newswire data? Click here to see licensing options. Don't Miss Any Updates
2019-05-02 · Senior Director Investor Relations (781) 419-1881 investors@repligen.com.
Jag vill bli optiker
ekonomie kandidat nationalekonomi jobb
ifs a se
dna translation diagram
spindler ag 2021
- Si swedish institute
- Arbetshandskar barn
- Basta long beach
- Hostar upp mycket slem
- Privat eller kommunal forskola
Repligen and Navigo target next-wave COVID vaccines with affinity resin. Dan Stanton BioProcess International: December 17, 2020: America's Best Mid-size Companies Repligen: #15. Andrea Murphy, Hank Tucker Forbes: November 19, 2020: Repligen CEO Tony Hunt Knows Why Success Takes Time: Marilyn Munch Investor's Business Daily: October 28, 2020
NGL COVID-19 Spike Protein Affinity Resin binds the SARS-CoV-2 Spike Protein receptor binding domain (RBD) to yield exceptional purity in a single chromatography step.